Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H), a clinical-stage oncology company, is advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. The company is focused on Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance. Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours. More information is available on the company’s website at https://oncoinnovations.com.
The DDR therapy approach represents a significant shift in oncology, focusing on the mechanisms cancer cells use to repair DNA damage and survive. By inhibiting PNKP, Onco-Innovations aims to disrupt these repair pathways, potentially making cancer cells more susceptible to treatment and overcoming resistance. This strategy could lead to more effective therapies for patients with solid tumours.
Investors can find the latest news and updates relating to ONNVF in the company’s newsroom at https://ibn.fm/ONNVF. The full article detailing Onco-Innovations’ approach is available at https://ibn.fm/D8pRO.
Onco-Innovations’ dual-platform approach, combining drug development with AI, positions the company to leverage data-driven insights for precision oncology. AI technologies can aid in identifying patient populations most likely to benefit from DDR therapies, optimizing clinical trials, and accelerating the development of personalized treatment plans. This integration of AI into oncology research is a growing trend that holds promise for improving patient outcomes.
As Onco-Innovations continues to develop its PNKP inhibitors and AI capabilities, the company is contributing to the broader effort to combat cancer through innovative science and technology. The announcement highlights the potential of DDR therapies and AI in transforming cancer care, offering hope for more effective and personalized treatments in the future.
